IDXGD (Interpace Biosciences) Growth Rank: 1 (As of Aug. 29, 2026) — 67% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IDXGD Interpace Biosciences Inc IDXGD
41 GF Score
Price $7.62
GF Value $0.20
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Interpace Biosciences Growth Rank?

Interpace Biosciences IDXGD +5.08% 41 Growth Rank is 1 as of Aug. 29, 2026, which is 67% below its 10-year median of 3.00. GuruFocus rates IDXGD with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Interpace Biosciences has the Growth Rank of 1.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Interpace Biosciences Growth Rank Related Terms

IDXGD vs PRPO, ADVB, BIOQ: Growth Rank Comparison

For the Diagnostics & Research subindustry, Interpace Biosciences's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Interpace Biosciences Growth Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Growth Rank distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Growth Rank falls into.


IDXGD
41GF Score
Interpace Biosciences Inc IDXGD
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 1 mean?
Interpace Biosciences (IDXGD) has a Growth Rank of 1 as of Aug. 29, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Interpace Biosciences and its competitors. This is 67% below median its historical median of 3.00. Over the past decade, Interpace Biosciences' Growth Rank has ranged from 1.00 to 9.00.
Is Interpace Biosciences' Growth Rank too high?
Interpace Biosciences' current Growth Rank of 1 is 67% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Growth Rank compare to PRPO and ADVB?
Interpace Biosciences' Growth Rank of 1 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Interpace Biosciences' own Growth Rank has ranged from 1.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Diagnostics & Research company?
A good Growth Rank depends on the Medical Diagnostics & Research industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Interpace Biosciences and its competitors. Interpace Biosciences's current Growth Rank is 1, which is 67% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXGD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $7.62 — trading 3709% above its estimated fair value. The current Growth Rank is 1, which is 67% below median its 10-year median of 3.00. Interpace Biosciences' overall GF Score™ is 41/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Interpace Biosciences (IDXGD), the current Growth Rank is 1 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Interpace Biosciences (IDXGD) Overvalued in 2026?

Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued. The current stock price of $7.62 is trading 3709% above its estimated GF Value™ of $0.20. GuruFocus considers Interpace Biosciences to be Significantly Overvalued.

Key valuation signals for IDXGD:

  • Growth Rank: 1 (67% below median its 10-year median of 3.00)
  • GF Value™: $0.20 vs. price of $7.62 (3709% above fair value)
  • GF Score™: 41/100 with 8 warning signs

No single metric tells the full story. See the IDXGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Interpace Biosciences Business Description

Other Exchanges PF42:Germany
Address 2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score

Get the complete analysis for IDXGD

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.62
Price
$0.20
GF Value